Silodosin

Product Description

CAS number: 160970-54-7

Chemical Formula: C25H32F3N3O4

Treatment for symptomatic relief of benign prostatic hyperplasiaBenign prostate hyperplasia (BPH), or an enlarged prostate, is a condition found only in men and is characterized by a non-cancerous enlargement of the prostate gland. Symptoms of BPH include urinary difficulty, urinary frequency and an inability to complete bladder emptying. Silodosin is highly uroselective for the alpha (1A) receptors located in the prostate, [urethrea and bladder trigone in the lower urinary tract]. Blocking these receptors relaxes the smooth muscles, resulting in an improvement in urine flow and a reduction in BPH symptoms. The selective binding of silodosin to the alpha (1A) receptors is substantially greater than the binding to the cardiovascular-associated alpha (1B) receptors and thereby maximizes target organ activity while minimizing the potential for blood pressure effects. [Watson Pharmaceutical Inc. Press release] Silodosin is alpha 1A-adrenoceptor selective antagonist which inhibits sympathetic nerve stimulation and relaxation of smooth muscle tone in the lower urinary tract which relieves the pressure from contraction of smooth muscle. The reduction of intraurethral pressure improves voiding and storage issues associated with BPH.

High Standards in Quality Control

Our Silodosin adheres to stringent impurity and microbial specifications. Utilizing advanced processes, the product contains single impurities of 0.10% and related substances 0.2%. Microbial counts and endotoxins remain well below accepted thresholds, ensuring safety for pharmaceutical applications.


Reliable Stability and Packaging

Packaged securely in HDPE drums or as specified by customers, Silodosin maintains its stability for up to 24 months when stored in tightly sealed containers, shielded from light and moisture. This guarantees consistent performance throughout its shelf life.


Therapeutic Application in BPH

Widely recognized for its effectiveness, Silodosin is a trusted choice for the management of benign prostatic hyperplasia. Its purity and performance support optimal therapeutic outcomes, making it a preferred API among healthcare manufacturers.